• Publications
  • Influence
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
New evidence and consensus has led to further revision of the McDonald Criteria for diagnosis of multiple sclerosis. The use of imaging for demonstration of dissemination of central nervous systemExpand
  • 7,461
  • 350
  • PDF
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
The International Panel on MS Diagnosis presents revised diagnostic criteria for multiple sclerosis (MS). The focus remains on the objective demonstration of dissemination of lesions in both time andExpand
  • 6,311
  • 300
  • PDF
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
New diagnostic criteria for multiple sclerosis integrating magnetic resonance image assessment with clinical and other paraclinical methods were introduced in 2001. The “McDonald Criteria” have beenExpand
  • 4,634
  • 203
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
BACKGROUND An evolving understanding of the immunopathogenesis of multiple sclerosis suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a humanized monoclonalExpand
  • 716
  • 56
  • PDF
Randomized trial of oral teriflunomide for relapsing multiple sclerosis.
BACKGROUND Teriflunomide is a new oral disease-modifying therapy for relapsing forms of multiple sclerosis. METHODS We concluded a randomized trial involving 1088 patients with multiple sclerosis,Expand
  • 687
  • 48
  • PDF
Ocrelizumab versus Interferon Beta‐1a in Relapsing Multiple Sclerosis
BACKGROUND B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody that selectively depletes CD20+ B cells. METHODS In two identical phase 3 trials,Expand
  • 656
  • 40
  • PDF
Defining the clinical course of multiple sclerosis
Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment of clinical trials, and treatmentExpand
  • 853
  • 36
  • PDF
Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis
we studied copolymer 1 (Copaxone) in a multicenter (11-university) phase III trial of patients with relapsing-remitting multiple sclerosis (MS). Two hundred fifty-one patients were randomized toExpand
  • 1,612
  • 32
European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients
Two prior double‐blind, placebo‐controlled, randomized trials demonstrated that glatiramer acetate (GA) reduces relapse rates in patients with relapsing remitting multiple sclerosis (RRMS). ThisExpand
  • 724
  • 26
Serial proton magnetic resonance spectroscopic imaging, contrast‐enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis
Serial magnetic resonnce (MR) studies that included proton MR spectroscopic imaging (MRSI), contrast‐enhanced MR imaging (MRI), and lesion volumetric studies were performed on 25 multiple sclerosisExpand
  • 309
  • 21